scholarly journals Beyond Growth Factors: Macrophage-Centric Strategies for Angiogenesis

2020 ◽  
Vol 8 (4) ◽  
pp. 111-120
Author(s):  
Alexis L. Nolfi ◽  
Marissa N. Behun ◽  
Cecelia C. Yates ◽  
Bryan N. Brown ◽  
Mangesh Kulkarni
Keyword(s):  
Growth Factors ◽  
Clinical Outcome ◽  
Host Response ◽  
Therapeutic Angiogenesis ◽  
Angiogenic Growth Factors ◽  
Therapeutic Goal ◽  
Pathological Conditions ◽  
Macrophage Phenotypes

AbstractFunctional angiogenesis is a critical therapeutic goal in many pathological conditions. Logically, the use of pro-angiogenic growth factors has been the mainstay approach despite obvious limitations and modest success. Recently, macrophages have been identified as key regulators of the host response to implanted materials. Particularly, our understanding of dynamically plastic macrophage phenotypes, their interactions with biomaterials, and varied roles in different stages of angiogenic processes is evolving rapidly. In this review, we discuss changing perspectives on therapeutic angiogenesis, in relation to implantable materials and macrophage-centric strategies therein. Harnessing the different mechanisms through which the macrophage-driven host response is involved in angiogenesis has great potential for improving clinical outcome.

Therapeutic Angiogenesis for Limb Ischemia Using Angiogenic Growth Factors and Carriers

2015 ◽  
Vol 4 (1) ◽  
pp. 57-63
Author(s):  
Shingo Nakamura ◽  
Masahiro Sato ◽  
Hidemi Hattori ◽  
Masafumi Shimizu ◽  
Masanori Fujita ◽  
...  
Keyword(s):  
Growth Factors ◽  
Limb Ischemia ◽  
Therapeutic Angiogenesis ◽  
Angiogenic Growth Factors

Angiogenesis in Ischemic Disease

1999 ◽  
Vol 82 (S 01) ◽  
pp. 44-52 ◽  
Author(s):  
Werner Risau ◽  
Hugo H. Marti
Keyword(s):  
Growth Factors ◽  
Blood Vessel ◽  
Vascular Development ◽  
Therapeutic Angiogenesis ◽  
Angiogenic Factors ◽  
Angiogenic Growth Factors ◽  
Edema Formation ◽  
Ischemic Disease ◽  
Naked Dna ◽  
Ischemic Diseases

SummaryAngiogenic growth factors and their endothelial receptors function as major regulators of blood vessel formation. The VEGF/VEGFR and the Angiopoietin/Tie2 receptor systems represent key signal transduction pathways involved in the regulation of embryonic vascular development. Inactivation of any of the genes encoding these molecules results in defective vascular development and lethality between embryonic day 8.5 and 12.5. In addition, VEGF and its receptors are also critically involved in the regulation of pathological blood vessel growth in the adult during various angiogenesis-dependent diseases that are associated with tissue hypoxia, such as solid tumor growth and ischemic diseases. It is now well established that therapeutic angiogenesis can be achieved in animal models of hind limb and myocardial ischemia by exogenously adding VEGF and/or other angiogenic growth factors. Available clinical data from human trials also suggests that patients with severe cardiovascular diseases could potentially benefit from such therapies. However, much more work needs to be done to compare the potency of different angiogenic factors or the combination thereof, as well as the best way of delivery, either as recombinant proteins, as naked DNA or via adenoviral vectors. Nevertheless, the therapeutic efficacy of simply injecting naked plasmid DNA or proteins into ischemic tissue to deliver secreted angiogenic factors is an encouraging finding. Time will show whether the adverse side effects of therapeutic angiogenesis, mainly vascular permeability and edema formation, can be minimized and angiogenic factors can be used as an effective therapy in patients for the treatment of ischemic diseases such as arterial occlusive disease, myocardial infarction, and, eventually, also stroke.

Therapeutic Angiogenesis: A New Frontier for Vascular Therapy

1996 ◽  
Vol 1 (1) ◽  
pp. 79-87 ◽  
Author(s):  
Jeffrey M Isner
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factors ◽  
Growth Factor ◽  
Therapeutic Angiogenesis ◽  
Vascular Endothelial ◽  
Hindlimb Ischemia ◽  
Angiogenic Growth Factors ◽  
New Frontier ◽  
Collateral Artery ◽  
Endothelial Growth Factor

Angiogenic cytokines constitute a potentially novel form of therapy for patients with cardiovascular disease. The feasibility of using recombinant formulations of angiogenic growth factors to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia – ‘therapeutic angiogenesis’ – has now been well established. These studies have suggested that two angiogenic growth factors in particular – basic fibroblast growth factor and vascular endothelial growth factor – are sufficiently potent to merit further investigation. More recently, experiments performed in our laboratory have indicated that, in the case of vascular endothelial growth factor – a secreted protein – similar results may be achieved by percutaneous arterial gene transfer. Further laboratory and clinical studies may yield promising insights into the fundamental basis for native as well as therapeutic angiogenesis, and at the same time more explicitly define the manner in which therapeutic angiogenesis may be successfully incorporated into clinical practice.

Role of Growth Factors and Endothelial Cells in Therapeutic Angiogenesis and Tissue Engineering

2006 ◽  
Vol 1 (3) ◽  
pp. 333-343 ◽  
Author(s):  
Masashi Nomi ◽  
Hideaki Miyake ◽  
Yoshifumi Sugita ◽  
Masato Fujisawa ◽  
Shay Soker
Keyword(s):  
Tissue Engineering ◽  
Endothelial Cells ◽  
Growth Factors ◽  
Therapeutic Angiogenesis

Angiogenesis: molecular mechanisms and functional interactions

2003 ◽  
Vol 89 (01) ◽  
pp. 190-197 ◽  
Author(s):  
Georg Breier ◽  
Hellmut Augustin
Keyword(s):  
Growth Factors ◽  
Research Program ◽  
Tumor Invasion ◽  
Molecular Mechanisms ◽  
Precursor Cells ◽  
Invasion And Metastasis ◽  
Angiogenic Growth Factors ◽  
Cell Contacts ◽  
Functional Interactions ◽  
Biannual Meeting

SummaryThe German Priority Research Program “Angiogenesis” (www.angiogenese.de) hosts a biannual meeting in the Kloster Seeon in Southern Germany. The 2nd Kloster Seeon Meeting “Angiogenesis: Molecular Mechanisms and Functional Interactions” was held in September 2002. It included sessions on hypoxia, the biology of endothelial precursor cells, angiogenic growth factors including VEGFs, the angiopoietins, ephrins, and FGFs, mechanisms of vascular sprouting and cell-cell contacts during angiogenesis, angiogenic signaling, lymphangiogenesis, angiogenesis during tumor invasion and metastasis, and on novel angiomanipulatory therapies. This report summarizes the key findings reported during the platform presentations of the meeting.

Sign in / Sign up

Export Citation Format

Share Document